hotspot -WSS

hotspot

author：explore 2025-10-01 15:28:50 - browse：416

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Iowa House, Senate pass 6

focus

WSS

New research casts further doubt on a common procedure used with IVF

How AI can help patients find reliable information about doctors

Roivant's CEO is a star, but biotech's black hole persists

Roche drug slashes death risk in early

Palantir health business leans on meeting customers’ needs

It's time to get medical device identifiers over the finish line

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

How the political right came to back psychedelics to treat trauma

23andMe had bad news about my health. I wish a person had delivered it

NIH fellows want a pay raise. Will that mean less money for grants?

Trump demands the U.S. pay no more for drugs than other countries … again

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

ChatGPT in medicine: STAT answers readers' burning questions

California’s proposed $25 per hour health care minimum wage

focus

ADCs take center stage as promising cancer treatments

Palantir health business leans on meeting customers’ needs

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Charles Manson follower Leslie Van Houten released from prison after 53 years

UnitedHealth, Optum discontinue NaviHealth name

focus

focus

focus

hotspot